Zhai, Bing http://orcid.org/0000-0001-6571-7465
Ola, Mihaela
Rolling, Thierry http://orcid.org/0000-0002-0277-5067
Tosini, Nicholas L.
Joshowitz, Sari
Littmann, Eric R.
Amoretti, Luigi A.
Fontana, Emily
Wright, Roberta J.
Miranda, Edwin
Veelken, Charlotte A.
Morjaria, Sejal M.
Peled, Jonathan U.
van den Brink, Marcel R. M.
Babady, N. Esther
Butler, Geraldine
Taur, Ying http://orcid.org/0000-0002-6601-8284
Hohl, Tobias M. http://orcid.org/0000-0002-9097-5412
Funding for this research was provided by:
Geoffrey Beene Cancer Research Center
Burroughs Wellcome Fund
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI093808, R01 AI139632, R01 AI137269)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
Deutsche Forschungsgemeinschaft (RO5328/2-1)
Science Foundation Ireland (12/IA/1343)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 13 July 2019
Accepted: 19 November 2019
First Online: 6 January 2020
Competing interests
: T.M.H. has participated in scientific advisory boards for Merck & Co, Inc. and Partner Therapeutics. J.U.P. reports research funding, intellectual property fees and travel reimbursement from Seres Therapeutics. M.R.M.v.d.B. has received research support from Seres Therapeutics, consulted, received honoraria from or participated in advisory boards for Seres Therapeutics, Flagship Ventures, Novartis, Evelo, Jazz Pharmaceuticals, Therakos, Amgen, Magenta Therapeutics, Merck & Co, Inc., Acute Leukemia Forum and the DKMS Medical Council (Board), and IP Licensing with Seres Therapeutics and Juno Therapeutics. All other authors have no competing interests.